A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Metastatic Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Contact: Study coordinator (Shukui Qin, Prof.)
Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Jihui Hao, Prof.)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC

Abroad (travel likely)RecruitingPHASE3

Tampa, United States · Atlanta, United States

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Pancreatic Cancer · Metastatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Winston-Salem, United States

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Beijing, China · Guangzhou, China

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Melbourne, Australia · Richmond, Australia